<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cam470977" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40411278</article-id><article-id pub-id-type="pmc">PMC12102611</article-id><article-id pub-id-type="doi">10.1002/cam4.70977</article-id><article-id pub-id-type="publisher-id">CAM470977</article-id><article-id pub-id-type="other">CAM4-2024-08-4791.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>
<styled-content style="fixed-case" toggle="no">PUF60</styled-content>&#x02010;Regulated Isoform Switching of <styled-content style="fixed-case" toggle="no">MAZ</styled-content> Modulates Gastric Cancer Cell Migration</article-title></title-group><contrib-group><contrib id="cam470977-cr-0001" contrib-type="author"><name><surname>Xing</surname><given-names>Dong</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0002" contrib-type="author"><name><surname>Zhao</surname><given-names>Ting</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0003" contrib-type="author"><name><surname>Mao</surname><given-names>Chenchen</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0004" contrib-type="author"><name><surname>Han</surname><given-names>Zheng</given-names></name><xref rid="cam470977-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470977-cr-0005" contrib-type="author"><name><surname>Cai</surname><given-names>Wanxia</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0006" contrib-type="author"><name><surname>Zhang</surname><given-names>Teming</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0007" contrib-type="author"><name><surname>Mei</surname><given-names>Dianfeng</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0008" contrib-type="author"><name><surname>Xie</surname><given-names>Wangkai</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0009" contrib-type="author"><name><surname>Yu</surname><given-names>Jiaye</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0010" contrib-type="author"><name><surname>Wu</surname><given-names>Zhonghan</given-names></name><xref rid="cam470977-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470977-cr-0011" contrib-type="author"><name><surname>Chen</surname><given-names>Zhiyuan</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0012" contrib-type="author"><name><surname>Feng</surname><given-names>Shiyu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-9622-9726</contrib-id><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470977-cr-0013" contrib-type="author"><name><surname>Shen</surname><given-names>Xian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3331-1676</contrib-id><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470977-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cam470977-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam470977-cr-0014" contrib-type="author" corresp="yes"><name><surname>Xue</surname><given-names>Xiangyang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-3241-5282</contrib-id><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cam470977-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>wzxxy@wmu.edu.cn</email></address></contrib><contrib id="cam470977-cr-0015" contrib-type="author" corresp="yes"><name><surname>Xiang</surname><given-names>Dan</given-names></name><xref rid="cam470977-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>xiangdan@wmu.edu.cn</email></address></contrib></contrib-group><aff id="cam470977-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Wenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer&#x02010;Related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences</named-content>
<institution>Wenzhou Medical University</institution>
<city>Wenzhou</city>
<country country="CN">China</country>
</aff><aff id="cam470977-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of General Surgery</named-content>
<institution>The First Affiliated Hospital of Wenzhou Medical University</institution>
<city>Wenzhou</city>
<country country="CN">China</country>
</aff><aff id="cam470977-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of General Surgery</named-content>
<institution>The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University</institution>
<city>Wenzhou</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Xiangyang Xue (<email>wzxxy@wmu.edu.cn</email>)<break/>
Dan Xiang (<email>xiangdan@wmu.edu.cn</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>14</volume><issue seq="370">11</issue><issue-id pub-id-type="doi">10.1002/cam4.v14.11</issue-id><elocation-id>e70977</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>21</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>08</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAM4-14-e70977.pdf"/><abstract><title>ABSTRACT</title><sec id="cam470977-sec-1001"><title>Background</title><p>As an essential transcription factor, Myc&#x02010;associated zinc&#x02010;finger protein (MAZ) is frequently upregulated in many human tumors and is a well&#x02010;documented oncogene.&#x02009;However, we found high expression of MAZ was closely associated with good survival outcomes in patients with stomach adenocarcinoma (STAD), and the underlying mechanism involved remains to be elucidated. We hypothesize that alternative splicing of MAZ plays an important role.</p></sec><sec id="cam470977-sec-1002"><title>Methods</title><p>Pan&#x02010;cancer analysis of MAZ expression and prognostic significance was performed using The Cancer Genome Atlas (TCGA) data, with emphasis on its divergent prognostic impact in gastric cancer (GC). MAZ protein levels were further validated in 356 GC tissue samples via immunohistochemistry. Functional investigations encompassed MAZ knockout (KO) and isoform&#x02010;specific rescue experiments to assess GC cell migration, alongside quantification of MAZ alternative splicing rates (PSI). Additionally, RNA immunoprecipitation sequencing (RIP&#x02010;seq) identified PUF60&#x02010;mediated regulation of MAZ isoforms.</p></sec><sec id="cam470977-sec-1003"><title>Results</title><p>MAZ was upregulated in GC but served as an independent protective prognostic factor. MAZ&#x02010;KO enhanced GC cell migration, while isoform&#x02010;specific re&#x02010;expression revealed divergent roles: MAZ&#x02010;2 promoted migration, whereas MAZ&#x02010;1 and MAZ&#x02010;3 suppressed it. Notably, MAZ&#x02010;2 is highly expressed in GC and is associated with poor survival prognosis of patients. Lower PSI values of MAZ&#x02010;2 were detected in GC. MAZ transcripts were directly bound by PUF60. PUF60 knockdown caused MAZ splice isoform switch, thereby enhancing GC cell migration.</p></sec><sec id="cam470977-sec-1004"><title>Conclusion</title><p>The prognostic difference of MAZ in GC stems from isoform&#x02010;specific functional antagonism, with cell migration phenotypes governed by the MAZ&#x02010;1/3 versus MAZ&#x02010;2 ratio. Targeting MAZ alternative splicing, particularly via PUF60 modulation, represents a novel therapeutic strategy.</p></sec></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="cam470977-blkfxd-0001"><graphic xlink:href="CAM4-14-e70977-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam470977-kwd-0001">alternative splicing</kwd><kwd id="cam470977-kwd-0002">cell migration</kwd><kwd id="cam470977-kwd-0003">gastric cancer</kwd><kwd id="cam470977-kwd-0004">isoform</kwd><kwd id="cam470977-kwd-0005">Myc&#x02010;associated zinc&#x02010;finger protein</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Zhejiang Provincial Natural Science Foundation of China</funding-source><award-id>LQ20H190003</award-id><award-id>LQ23H160017</award-id><award-id>Q24H160147</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Key Research and Development Program of Zhejiang Province
</institution><institution-id institution-id-type="doi">10.13039/100022963</institution-id></institution-wrap></funding-source><award-id>2021C03120</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>32070151</award-id></award-group><award-group id="funding-0004"><funding-source>Wenzhou Municipal Science and Technology Bureau Program</funding-source><award-id>2023Y1621</award-id><award-id>ZY2022015</award-id></award-group></funding-group><counts><fig-count count="7"/><table-count count="1"/><page-count count="12"/><word-count count="6200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:24.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cam470977-ntgp-0001"><fn fn-type="funding" id="cam470977-note-0001"><p>
<bold>Funding:</bold> This study was supported by grants from the National Natural Science Foundation of China (Grant No: 32070151), the Key R&#x00026;D Program of Zhejiang Province (Grant No: 2021C03120), the Zhejiang Provincial Natural Science Foundation of China (Grant Nos. LQ20H190003, LQ23H160017, Q24H160147), and the Wenzhou Municipal Science and Technology Bureau Program (2023Y1621, ZY2022015).</p></fn><fn fn-type="equal" id="cam470977-note-0002"><p>Dong Xing, Ting Zhao, Chenchen Mao and Zheng Han have contributed equally to this work.</p></fn></fn-group></notes></front><body id="cam470977-body-0001"><sec id="cam470977-sec-0001"><label>1</label><title>Introduction</title><p>Gastric cancer (GC) is the fifth most common cancer type and the fourth leading cause of cancer death globally [<xref rid="cam470977-bib-0001" ref-type="bibr">1</xref>]. Due to the high molecular and phenotypic heterogeneity of GC, surgical resection is the preferred treatment [<xref rid="cam470977-bib-0002" ref-type="bibr">2</xref>]. However, most patients with advanced GC often have lost the opportunity for surgery. Fortunately, the molecular classification of GC has provided an opportunity for patients to receive personalized treatment. Current targeted agents for GC include trastuzumab to treat HER&#x02010;2 positive patients and programmed death receptor&#x02010;1 (PD&#x02010;1) inhibitor nivolumab to treat patients with microsatellite high instability [<xref rid="cam470977-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470977-bib-0003" ref-type="bibr">3</xref>], which have effectively prolonged overall and disease&#x02010;free survival. However, these subgroups represent only a small fraction of GC, and novel GC therapeutic targets are urgently needed.</p><p>MAZ is a zinc finger protein ubiquitously expressed in various tissues of the human body, and it contains six C2H2 zinc fingers that bind to GA boxes on the promoter of target genes [<xref rid="cam470977-bib-0004" ref-type="bibr">4</xref>]. MAZ has been shown to regulate the expression of a large number of genes, such as proto&#x02010;oncogene c&#x02010;myc [<xref rid="cam470977-bib-0005" ref-type="bibr">5</xref>], TP53 [<xref rid="cam470977-bib-0006" ref-type="bibr">6</xref>], Ras family gene [<xref rid="cam470977-bib-0007" ref-type="bibr">7</xref>], human telomerase reverse transcriptase (hTERT) [<xref rid="cam470977-bib-0008" ref-type="bibr">8</xref>], vascular endothelial growth factor (VEGF) [<xref rid="cam470977-bib-0009" ref-type="bibr">9</xref>], and cluster of differentiation 4 (CD4) [<xref rid="cam470977-bib-0010" ref-type="bibr">10</xref>], through the dual effects of transcriptional activation and transcriptional termination. Additionally, MAZ is involved in tumor progression by directly binding to the promoter regions of target genes or synergizing with other transcription factors. It has been identified as an oncogene in several tumor types, including hepatocellular carcinoma [<xref rid="cam470977-bib-0011" ref-type="bibr">11</xref>], prostate cancer [<xref rid="cam470977-bib-0012" ref-type="bibr">12</xref>], breast cancer [<xref rid="cam470977-bib-0013" ref-type="bibr">13</xref>], and glioblastoma [<xref rid="cam470977-bib-0014" ref-type="bibr">14</xref>]. There has been evidence that knockdown of MAZ expression inhibits cell proliferation, invasion, migration, and angiogenesis [<xref rid="cam470977-bib-0015" ref-type="bibr">15</xref>]. In addition, MAZ was identified as an insulator&#x02010;like factor in genome organization, which is essential for the regulation of global genes, and was an indispensable gene for normal development [<xref rid="cam470977-bib-0016" ref-type="bibr">16</xref>]. These results suggest that MAZ might be a promising therapeutic target in these tumors.</p><p>Alternative splicing is an essential mechanism for regulating gene expression in eukaryotes, and more than 95% of human genes cannot be expressed normally without the splicing of pre&#x02010;mRNA [<xref rid="cam470977-bib-0017" ref-type="bibr">17</xref>]. In recent years, the abnormal regulation of alternative splicing in cancer initiation and progression has become a tumor marker [<xref rid="cam470977-bib-0018" ref-type="bibr">18</xref>]. Through alternative splicing, a single gene can produce a variety of mature mRNA with entirely different structures and functions, which significantly increases the diversity of proteins. For example, Bcl&#x02010;x (L) produced in Bcl&#x02010;x pre&#x02010;mRNA has anti&#x02010;apoptotic ability, while Bcl&#x02010;x (S) can promote apoptosis [<xref rid="cam470977-bib-0019" ref-type="bibr">19</xref>]. In addition, alternative splicing of EGFR, KRAS, HRAS, TP53, CD44, and other genes has been reported, which affect almost any stage of tumorigenesis and progression [<xref rid="cam470977-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470977-bib-0020" ref-type="bibr">20</xref>, <xref rid="cam470977-bib-0021" ref-type="bibr">21</xref>, <xref rid="cam470977-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470977-bib-0023" ref-type="bibr">23</xref>]. The MAZ gene encodes three isoforms, MAZ&#x02010;1, MAZ&#x02010;2, and MAZ&#x02010;3, which are highly regulated by alternative splicing [<xref rid="cam470977-bib-0024" ref-type="bibr">24</xref>, <xref rid="cam470977-bib-0025" ref-type="bibr">25</xref>]. Still, nowadays, most studies on the function of MAZ have focused mainly on MAZ&#x02010;1, which has a transcriptional activation function [<xref rid="cam470977-bib-0004" ref-type="bibr">4</xref>]. However, MAZ&#x02010;2 could function as a transcriptional repressor of MAZ&#x02010;1 [<xref rid="cam470977-bib-0024" ref-type="bibr">24</xref>]. Some studies have found that the expression ratio of the three isoforms of MAZ can be changed in inflammation, suggesting that the functions of the isoforms are different [<xref rid="cam470977-bib-0025" ref-type="bibr">25</xref>]. The functional contribution of MAZ splice isoforms in cancer has not been investigated.</p><p>In the present study, we sought to elucidate the expression, clinical correlation, biological function, and potential alternative splicing mechanisms of MAZ in GC. Public databases and clinical samples have confirmed that MAZ expression is upregulated in GC but is associated with improved patient outcomes. We verified that MAZ played an important role in GC metastasis. Among them, MAZ&#x02010;2 significantly promoted GC cell migration, while MAZ&#x02010;1 and MAZ&#x02010;3 had opposite functions. Splicing factor PUF60 is involved in the alternative splicing of MAZ. Our results explain the difference in the prognostic value of MAZ in GC, and the phenotype of GC cell migration can be modulated at the level of the MAZ isoform ratio.</p></sec><sec sec-type="materials-and-methods" id="cam470977-sec-0002"><label>2</label><title>Materials and Methods</title><p>Materials and methods are described in Data <xref rid="cam470977-supitem-0001" ref-type="supplementary-material">S1</xref>, including the sequences for sgRNAs and specific primers (Tables&#x000a0;<xref rid="cam470977-supitem-0003" ref-type="supplementary-material">S1</xref> and <xref rid="cam470977-supitem-0004" ref-type="supplementary-material">S2</xref>).</p></sec><sec sec-type="results" id="cam470977-sec-0003"><label>3</label><title>Results</title><sec id="cam470977-sec-0004"><label>3.1</label><title>Pan&#x02010;Cancer <styled-content style="fixed-case" toggle="no">MAZ</styled-content> Expression and Associations With Survival</title><p>To evaluate the MAZ expression in pan&#x02010;cancer, we first analyzed MAZ mRNA expression between tumor and adjacent normal tissues via the TIMER database [<xref rid="cam470977-bib-0026" ref-type="bibr">26</xref>]. The results showed high MAZ expression in 15 tumor types including BRCA, BLCA, CESC, CHOL, ESCA, HNSC, KIRC, KIRP, LIHC, LUSC, LUAD, PCPG, PRAD, STAD, and UCEC (Figure&#x000a0;<xref rid="cam470977-fig-0001" ref-type="fig">1A</xref>). Considering the small number of normal tissues in the TCGA database, we used the GEPIA database [<xref rid="cam470977-bib-0027" ref-type="bibr">27</xref>], which integrates TCGA and GTEx data, to further validate the results. MAZ expression was significantly increased in 24 of 33 tumor types, except for ACC, CHOL, KICH, LAML, MESO, PCPG, SARC, THCA, and UVM (Figure&#x000a0;<xref rid="cam470977-fig-0001" ref-type="fig">1B</xref>). We further explored the relationship between MAZ expression level and prognosis in 13 malignant tumors with up&#x02010;regulation of MAZ in both the TIMER and GEPIA databases. Univariate COX regression analysis illustrated MAZ as a high&#x02010;risk gene in BLCA, KIRC, KIRP, LIHC, and LUSC, but a low&#x02010;risk gene in STAD (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, HR&#x02009;=&#x02009;0.525) and ESCA (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.047, HR&#x02009;=&#x02009;0.613) (Figure&#x000a0;<xref rid="cam470977-fig-0001" ref-type="fig">1C</xref>). As previously reported, MAZ was a cancer&#x02010;promoting gene in many malignant tumors [<xref rid="cam470977-bib-0015" ref-type="bibr">15</xref>]. However, high expression of MAZ is most significantly associated with better prognosis in gastric cancer (GC) (Figure&#x000a0;<xref rid="cam470977-fig-0001" ref-type="fig">1D&#x02013;P</xref>). To explain the difference in prognosis value of MAZ in GC, we next explored the role of MAZ in GC.</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0001"><label>FIGURE 1</label><caption><p>MAZ expression and associations with survival in pan&#x02010;cancer. (A) The expression of MAZ from 33 types of cancer samples and corresponding normal samples in the TIMER database. (B) The expression of MAZ from 33 types of cancer samples and corresponding normal samples in the GEPIA database. (C) The correlation between MAZ expression and OS in 13 MAZ&#x02010;upregulated tumors. (D&#x02013;P) Kaplan&#x02013;Meier analysis of the association between MAZ expression and OS in 13 MAZ&#x02010;upregulated tumors.</p></caption><graphic xlink:href="CAM4-14-e70977-g002" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="cam470977-sec-0005"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">MAZ</styled-content> Upregulation in <styled-content style="fixed-case" toggle="no">GC</styled-content> but Correlates With Improved Patient Outcomes</title><p>We detected the expression of the MAZ gene by immunohistochemistry (IHC) in our archived GC tissue microarray and found that MAZ was expressed mainly in the nucleus of cancer cells (Figure&#x000a0;<xref rid="cam470977-fig-0002" ref-type="fig">2A</xref>). To analyze the expression of MAZ in detail, the IHC results were scored by the H&#x02010;score method. MAZ was highly expressed in tumor tissues compared with adjacent normal tissues (Figure&#x000a0;<xref rid="cam470977-fig-0002" ref-type="fig">2B,C</xref>). According to the different H&#x02010;scores, patients with GC were divided into the MAZ high expression group (<italic toggle="yes">n</italic>&#x02009;=&#x02009;240) and the MAZ low expression group (<italic toggle="yes">n</italic>&#x02009;=&#x02009;116). It was shown that patients with MAZ high expression had better T&#x02010;stage (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.026), better TNM stage (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001), and smaller tumor size (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) than those with MAZ low expression; no significant correlations were observed between MAZ and gender, age, N stage, or differentiation (<italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05) (Table&#x000a0;<xref rid="cam470977-tbl-0001" ref-type="table">1</xref>). Kaplan&#x02013;Meier survival analysis showed that patients with MAZ high expression had more prolonged overall survival (OS) than those with low MAZ expression (Figure&#x000a0;<xref rid="cam470977-fig-0002" ref-type="fig">2D</xref>). Moreover, multivariate analysis revealed that high expression of MAZ was an independent protective predictor of OS (Figure&#x000a0;<xref rid="cam470977-fig-0002" ref-type="fig">2E,F</xref>). These results indicate that MAZ upregulation in GC is associated with better prognosis in patients with GC.</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0002"><label>FIGURE 2</label><caption><p>MAZ expression and associations with survival in GC. (A) Representative picture of the IHC staining of MAZ proteins in GC and normal tissues. Scale bar, 500&#x02009;&#x003bc;m (low magnification) or 50&#x02009;&#x003bc;m (high magnification). (B) Compared MAZ H&#x02010;scores in GC tissues (<italic toggle="yes">n</italic>&#x02009;=&#x02009;356) and adjacent normal tissues (<italic toggle="yes">n</italic>&#x02009;=&#x02009;36). (C) Compared MAZ H&#x02010;scores in paired GC tissues and adjacent normal tissues (<italic toggle="yes">n</italic>&#x02009;=&#x02009;36). (D) Kaplan&#x02013;Meier curve showed MAZ gene expression predicted better OS (<italic toggle="yes">n</italic>&#x02009;=&#x02009;356, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001) in patients with GC. (E, F) Univariate and multivariate Cox regression analysis of OS in patients with GC.</p></caption><graphic xlink:href="CAM4-14-e70977-g004" position="anchor" id="jats-graphic-5"/></fig><table-wrap position="float" id="cam470977-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Clinicopathological features and MAZ in GC.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Variables</th><th align="center" colspan="3" valign="bottom" rowspan="1">MAZ expression</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Low (<italic toggle="yes">n</italic>&#x02009;=&#x02009;116, 32.6%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">High (<italic toggle="yes">n</italic>&#x02009;=&#x02009;240, 67.4%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Gender (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.664</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">87 (75.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">185 (77.1%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">29 (25.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (22.9%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;60</td><td align="center" valign="top" rowspan="1" colspan="1">31 (26.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (28.8%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;60</td><td align="center" valign="top" rowspan="1" colspan="1">85 (73.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">171 (74.2%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Depth of invasion (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.026<xref rid="cam470977-note-0003" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T1&#x02009;+&#x02009;T2&#x02009;+&#x02009;T3</td><td align="center" valign="top" rowspan="1" colspan="1">60 (52.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">153 (64.6%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T4</td><td align="center" valign="top" rowspan="1" colspan="1">55 (47.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (35.4%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Lymph node metastasis (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N0&#x02009;+&#x02009;N1&#x02009;+&#x02009;N2</td><td align="center" valign="top" rowspan="1" colspan="1">88 (76.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">197 (82.1%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N3</td><td align="center" valign="top" rowspan="1" colspan="1">27 (23.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (17.9%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>TNM stage (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001<xref rid="cam470977-note-0005" ref-type="table-fn">***</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">15 (13.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">83 (35.0%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II&#x02009;+&#x02009;III&#x02009;+&#x02009;IV</td><td align="center" valign="top" rowspan="1" colspan="1">99 (86.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">154 (65.0%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Differentiation status (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.153</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Well and moderate</td><td align="center" valign="top" rowspan="1" colspan="1">30 (25.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (33.3%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Poor</td><td align="center" valign="top" rowspan="1" colspan="1">86 (74.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">160 (66.7%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Tumor size (cm) (<italic toggle="yes">n</italic> [%])</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.004<xref rid="cam470977-note-0004" ref-type="table-fn">**</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;4</td><td align="center" valign="top" rowspan="1" colspan="1">42 (36.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">126 (52.9%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;4</td><td align="center" valign="top" rowspan="1" colspan="1">73 (63.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">112 (47.1%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="cam470977-ntgp-0002"><fn id="cam470977-note-0003"><label>*</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn><fn id="cam470977-note-0004"><label>**</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></fn><fn id="cam470977-note-0005"><label>***</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cam470977-sec-0006"><label>3.3</label><title>
<styled-content style="fixed-case" toggle="no">MAZ</styled-content> Inhibits the Migration of <styled-content style="fixed-case" toggle="no">GC</styled-content> Cells</title><p>To explore how MAZ might affect GC progression, we generated heterozygous MAZ knockout AGS and MKN&#x02010;45 GC cells (MAZ+/&#x02212;) by CRISPR/Cas9. Individual clone populations were screened for MAZ expression by western blot, and two independent clones without MAZ expression were obtained in AGS and MKN&#x02010;45, respectively (Figure&#x000a0;<xref rid="cam470977-fig-0003" ref-type="fig">3A</xref> and Figure&#x000a0;<xref rid="cam470977-supitem-0002" ref-type="supplementary-material">S1A</xref>). We observed that the growth rates of MAZ knockout cells (MAZ&#x02010;KO) and wide&#x02010;type cells (MAZ&#x02010;WT) were almost equal (Figure&#x000a0;<xref rid="cam470977-fig-0003" ref-type="fig">3B,C</xref> and Figure&#x000a0;<xref rid="cam470977-supitem-0002" ref-type="supplementary-material">S1B</xref>). Although there was heterogeneity in cell migration between the two independent clones, MAZ&#x02010;deficient cells showed significantly enhanced migration compared with MAZ&#x02010;WT cells (Figure&#x000a0;<xref rid="cam470977-fig-0003" ref-type="fig">3D</xref>). To examine the biological processes altered by MAZ, we performed RNA sequencing (RNA&#x02010;seq) in MAZ&#x02010;knockout AGS cells. As a result, a total of 608 differentially expressed genes (DEGs) were screened out, of which 384 DEGs were upregulated and 224 DEGs were down&#x02010;regulated (Figure&#x000a0;<xref rid="cam470977-fig-0003" ref-type="fig">3E</xref>). Gene ontology (GO) enrichment showed that in addition to being related to &#x0201c;immune response&#x0201d;, these DEGs were highly enriched for terms related to cell migration, such as &#x0201c;positive regulation of cell motility&#x0201d;, &#x0201c;positive regulation of cellular component movement&#x0201d;, &#x0201c;positive regulation of locomotion&#x0201d;, &#x0201c;positive regulation of cell migration&#x0201d;, &#x0201c;extracellular structure organization&#x0201d;, &#x0201c;extracellular matrix organization and chemotaxis&#x0201d; (Figure&#x000a0;<xref rid="cam470977-fig-0003" ref-type="fig">3F</xref>), and MAZ has been shown to regulate the production of pro&#x02010;tumor cytokines in LUAD, playing an important role in immune evasion [<xref rid="cam470977-bib-0028" ref-type="bibr">28</xref>]. Overall, this evidence above supports the inference that MAZ inhibits GC cell migration.</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0003"><label>FIGURE 3</label><caption><p>MAZ acts as a suppressor of cancer cell migration in GC progression. (A) Western blot analysis of MAZ knockout in AGS and MKN&#x02010;45 cells. (B, C) The proliferation of cells under MAZ knockout was determined via CCK&#x02010;8 assay and colony formation assay, respectively. (D) The migration of cells under MAZ knockout was determined via transwell assay. Scale bar, 100&#x02009;&#x003bc;m. (E) RNA&#x02010;seq in MAZ knockout AGS and control cells. Volcano plot showing 608 DEGs. (F) GO enrichment of DEGs between MAZ knockout AGS and control cells.</p></caption><graphic xlink:href="CAM4-14-e70977-g003" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="cam470977-sec-0007"><label>3.4</label><title>
<styled-content style="fixed-case" toggle="no">MAZ</styled-content> Isoforms Displayed Opposite Roles in <styled-content style="fixed-case" toggle="no">GC</styled-content> Cell Migration</title><p>In the MAZ gene family, three members that have been identified are formed by alternative splicing (Figure&#x000a0;<xref rid="cam470977-fig-0004" ref-type="fig">4A</xref>). Compared with MAZ&#x02010;1, MAZ&#x02010;2 is generated due to the retention of exon 6, and the difference in the carboxyl terminus confers two additional zinc fingers [<xref rid="cam470977-bib-0024" ref-type="bibr">24</xref>]. In addition, MAZ&#x02010;3 with different N termini was generated due to the different transcription start sites [<xref rid="cam470977-bib-0025" ref-type="bibr">25</xref>]. The structural differences of MAZ isoforms lead to different transcriptional activities [<xref rid="cam470977-bib-0025" ref-type="bibr">25</xref>]. We generated MAZ stable transfected GC cell lines AGS and MKN&#x02010;45 based on the tet&#x02010;on system, which could express MAZ&#x02010;1, MAZ&#x02010;2, and MAZ&#x02010;3 after doxycycline induction, respectively, and a HA tag was added to the C&#x02010;terminus of MAZ. Western blotting and immunofluorescence (IF) staining detected the overexpression of the MAZ isoform (Figure&#x000a0;<xref rid="cam470977-fig-0004" ref-type="fig">4B</xref> and Figure&#x000a0;<xref rid="cam470977-supitem-0002" ref-type="supplementary-material">S1C,D</xref>). Next, transwell assay and wound healing assay were performed to explore whether MAZ isoforms have an equal effect on cell migration. Notably, MAZ&#x02010;1 and MAZ&#x02010;3 overexpression significantly inhibited the migration of both GC cells, but overexpression of MAZ&#x02010;2 resulted in a marked increase in cell migration (Figure&#x000a0;<xref rid="cam470977-fig-0004" ref-type="fig">4C,D</xref>). Western blot results showed that overexpression of MAZ&#x02010;1 led to decreased expression levels of Vimentin and N&#x02010;cadherin, while overexpression of MAZ&#x02010;2 promoted the expression of Vimentin and N&#x02010;cadherin (Figure&#x000a0;<xref rid="cam470977-supitem-0002" ref-type="supplementary-material">S1E</xref>). Moreover, we reintroduced the gene into AGS MAZ KO#1 cells, and the transwell assay showed similar results. MAZ&#x02010;1 and MAZ&#x02010;3 re&#x02010;expression rescued the increased migration induced by MAZ&#x02010;KO. Conversely, the re&#x02010;expression of MAZ&#x02010;2 further enhanced GC cell migration (Figure&#x000a0;<xref rid="cam470977-fig-0004" ref-type="fig">4E</xref>).</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0004"><label>FIGURE 4</label><caption><p>MAZ&#x02010;1 and MAZ&#x02010;3 suppress GC cell migration while MAZ&#x02010;2 enhances GC cell migration. (A) Schematic of MAZ pre&#x02010;mRNA and MAZ splice isoforms. MAZ antibody&#x02010;targeting regions and zinc finger domains are indicated. (B) Western blot analysis of MAZ of AGS and MKN&#x02010;45 cells expressing MAZ&#x02010;1&#x02010;HA, MAZ&#x02010;2&#x02010;HA, or MAZ&#x02010;3&#x02010;HA. (C) Representative images from transwell assays with AGS and MKN&#x02010;45 cells expressing MAZ&#x02010;1&#x02010;HA, MAZ&#x02010;2&#x02010;HA, or MAZ&#x02010;3&#x02010;HA. Scale bar, 100&#x02009;&#x003bc;m. (D) Representative images from wound healing assays with AGS cells expressing MAZ&#x02010;1&#x02010;HA, MAZ&#x02010;2&#x02010;HA, or MAZ&#x02010;3&#x02010;HA. (E) Representative images from transwell assays with AGS MAZ&#x02010;KO cells re&#x02010;expressing MAZ&#x02010;1&#x02010;HA, MAZ&#x02010;2&#x02010;HA, or MAZ&#x02010;3&#x02010;HA. Scale bar, 100&#x02009;&#x003bc;m.</p></caption><graphic xlink:href="CAM4-14-e70977-g005" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="cam470977-sec-0008"><label>3.5</label><title>
<styled-content style="fixed-case" toggle="no">MAZ</styled-content> Isoform Ratio Is Associated With Patient Survival</title><p>Given the different effects of MAZ isoforms on GC cell migration, we investigated the distribution of their transcripts via the publicly available TCGA Splice Variant database (TSVdb) [<xref rid="cam470977-bib-0029" ref-type="bibr">29</xref>]. We found that in 314 GC patients, the abundance of MAZ&#x02010;2 mRNA was slightly higher than that of MAZ&#x02010;1 mRNA. In contrast, the abundance of MAZ&#x02010;3 mRNA was very low (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5A</xref>). In addition, we found that MAZ&#x02010;2 mRNA, which promotes tumor cell migration, was more abundant in GC tissues, while the abundance of MAZ&#x02010;1 and MAZ&#x02010;3 mRNA was not statistically different between tumor and adjacent normal tissues (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5B&#x02013;D</xref>). Because both MAZ&#x02010;1 and MAZ&#x02010;3 contributed to cell migration inhibition, we designed specific primers for the additional exon 6 of MAZ&#x02010;2, as shown in Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5E</xref>, and then examined the abundance of each MAZ transcript in eight paired pairs of GC tissues. Similar to these results obtained from the TCGA database, the mRNA level of MAZ&#x02010;2 was significantly higher in GC tissues than in the adjacent tissues (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5F,G</xref>). These findings led us to examine whether MAZ exon 6 skipping is associated with prognosis in patients with GC. We divided 445 GC patients in TCGA into percent&#x02010;splice&#x02010;in (PSI)&#x02010;high and PSI&#x02010;low groups based on the exon 6 skipping event, and patients in the PSI&#x02010;high group had a worse survival outcome (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5H</xref>). Taken together, we postulated that the differential effects of MAZ in GC prognosis might be related to diversity in MAZ isoform expression. Interestingly, except for KIRC, the MAZ&#x02010;2 isoform ratio in BLCA, KIRP, LIHC, and LUSC was significantly higher than that in STAD and ESCA. At the same time, MAZ was a protective factor for prognosis in STAD and ESCA and a risk factor for prognosis in BLCA, KIRP, LIHC, and LUSC. These results indicate that the MAZ isoform ratio is associated with patient survival (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5I</xref>).</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0005"><label>FIGURE 5</label><caption><p>MAZ isoform ratio is associated with patient survival. (A&#x02013;D) MAZ isoform mRNA levels in STAD patients derived from TCGA data. (E) Schematic of MAZ pre&#x02010;mRNA splicing. The positions of primers used in the RT&#x02010;PCR analysis of MAZ isoforms are indicated. (F, G) The expression levels of MAZ isoforms in 8 paired GC tissues and adjacent normal tissues were detected by RT&#x02010;PCR. (H) Kaplan&#x02013;Meier curves for overall survival in STAD and MAZ PSI values from the TCGASpliceSeq. The patients with high&#x02010;PSI had a worse survival outcome (<italic toggle="yes">n</italic>&#x02009;=&#x02009;445, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.015). PSI&#x02009;=&#x02009;splice&#x02010;in / (splice&#x02010;in&#x02009;+&#x02009;splice&#x02010;out). (I) MAZ&#x02010;2 isoform ratio of total is low in STAD and ESCA.</p></caption><graphic xlink:href="CAM4-14-e70977-g006" position="anchor" id="jats-graphic-11"/></fig></sec><sec id="cam470977-sec-0009"><label>3.6</label><title>Splicing Factor <styled-content style="fixed-case" toggle="no">PUF60</styled-content> Regulates Alternative Splicing of <styled-content style="fixed-case" toggle="no">MAZ</styled-content>
</title><p>To explore the underlying mechanism of MAZ alternative splicing in GC, a total of 504 co&#x02010;DEGs were obtained by using the GEO2R from GSE13911, GSE29272, and GSE30727 datasets. In addition, we examined the expression levels of splicing regulatory genes that have been reported [<xref rid="cam470977-bib-0030" ref-type="bibr">30</xref>]. Finally, we obtained four differentially splicing&#x02010;regulated genes in GC (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6A</xref>), which were IGF2BP3, PUF60, SNRPB, and SNRPF. Additionally, our RNA&#x02010;seq results suggested that overexpression of PUF60 in AGS cells resulted in 21,234 splicing events, including 9838 skipped exons, 2232 mutually exclusive exons, 2718 alternative 5&#x02032; splice sites, 3571 alternative 3&#x02032; splice sites, and 2875 retained introns, and PUF60 is involved in exon skipping in MAZ (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6B</xref>). Therefore, the splicing factor PUF60 was selected for further investigation. RNA immunoprecipitation sequencing (RIP&#x02010;Seq) assays were performed on AGS cells overexpressing PUF60&#x02010;HA with antibodies against HA&#x02010;tag to evaluate the accuracy of our RNA&#x02010;seq analysis in PUF60 splicing changes. As expected, PUF60 binding peaks are observed on each exon of the MAZ transcripts (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6C</xref>). Moreover, RIP&#x02010;PCR was conducted and confirmed that MAZ transcripts were directly bound by PUF60 (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6D,E</xref>).</p><fig position="float" fig-type="FIGURE" id="cam470977-fig-0006"><label>FIGURE 6</label><caption><p>Splicing factor PUF60 regulates alternative splicing of MAZ. (A) Co&#x02010;differentially expressed splicing regulatory gene in GSE13911, GSE29272, and GSE30727 datasets. (B) PUF60&#x02010;regulated AS events in AGS cells. The classification of alternative splicing events includes skipped exon (SE), alternative 5&#x002b9; splice site (A5SS), alternative 3&#x002b9; splice site (A3SS), mutually exclusive exon (MXE), and retained intron (RI). (C) Peak analysis identified RIP&#x02010;seq peaks on MAZ exons enriched by PUF60, which were shown as track signals in an integrative genomic viewer (hg38). (D, E) RIP&#x02010;PCR analysis of PUF60 binding sites. Isotype antibody was used as the control. (F&#x02013;H) The expression levels of MAZ isoforms in AGS cells with PUF60 knockdown were detected by RT&#x02010;PCR. I Representative images from transwell assays with knockdown of PUF60 in MAZ&#x02010;KO AGS or WT&#x02010;AGS cells. Scale bar, 100&#x02009;&#x003bc;m.</p></caption><graphic xlink:href="CAM4-14-e70977-g007" position="anchor" id="jats-graphic-13"/></fig><p>To explore the role of PUF60 in MAZ alternative splicing, we examined the expression of each MAZ isoform in PUF60&#x02010;silenced conditions. PUF60 knockdown led to increased expression of MAZ&#x02010;2 but decreased expression of MAZ&#x02010;1 and MAZ&#x02010;3 slightly (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6F&#x02013;H</xref>). As an essential splicing factor involved in the progression of various kinds of tumors [<xref rid="cam470977-bib-0031" ref-type="bibr">31</xref>], we speculated that PUF60 regulates the migratory phenotype of GC cells through alternative splicing of MAZ. Consistent with this hypothesis, the migration of GC cells was enhanced after knocking down PUF60 (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6I</xref>). Notably, when PUF60 was knocked down in MAZ&#x02010;KO cell lines, there was no significant change in cell migration (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6I</xref>).</p><p>In this study, we found that the MAZ&#x02010;2 isoform possessed potent pro&#x02010;tumor metastatic activity, whereas MAZ&#x02010;1 and MAZ&#x02010;3 have opposite effects in GC. The splicing factor PUF60 regulates alternative splicing of MAZ, and the phenotype of cell migration can be modulated at the level of MAZ alternative splicing. Our finding unravels that targeting MAZ alternative splicing is a potential therapeutic approach.</p></sec></sec><sec sec-type="discussion" id="cam470977-sec-0010"><label>4</label><title>Discussion</title><p>Gastric cancer (GC) is one of the most common malignant gastrointestinal tumors, and metastasis is the deadliest step in the progression of GC. Even after radical surgery, patients with advanced GC still face metastasis and recurrence, which often means a terrible outcome [<xref rid="cam470977-bib-0032" ref-type="bibr">32</xref>]. The factors involved in metastasis are very complex and multifaceted and are still not fully understood, making it difficult to inhibit the metastasis of GC effectively. Previous studies have detected that the activity of transcription factors (TFs) regulating normal stomach and GC has been implicated in GC invasiveness [<xref rid="cam470977-bib-0033" ref-type="bibr">33</xref>, <xref rid="cam470977-bib-0034" ref-type="bibr">34</xref>]. New studies have also shown that activation of a small set of TFs driving the mesenchymal phenotype plays an important role in GC progression [<xref rid="cam470977-bib-0034" ref-type="bibr">34</xref>, <xref rid="cam470977-bib-0035" ref-type="bibr">35</xref>]. Targeting TFs may represent potential therapeutic opportunities. This study is the first to systematically investigate the relationship between myc&#x02010;associated zinc&#x02010;finger protein (MAZ) isoforms and tumor metastasis, as well as the clinical and prognostic value in GC. Our results demonstrate that the prognosis suggested by MAZ is specific in GC across all TCGA tumors. MAZ, a member of the C2H2 transcription factor family, is involved in gene expression and tumor development. In prostate cancer, MAZ promotes bone metastasis through transcriptionally activating the KRas&#x02010;dependent RalGEFs pathway, and MAZ binds to the CDH1 promoter to promote epithelial&#x02010;mesenchymal transition (EMT) [<xref rid="cam470977-bib-0012" ref-type="bibr">12</xref>, <xref rid="cam470977-bib-0036" ref-type="bibr">36</xref>]. In glioblastoma, hepatocellular carcinoma, and neuroblastoma, MAZ is associated with the promotion of tumor cell migration and invasion [<xref rid="cam470977-bib-0015" ref-type="bibr">15</xref>]. However, in basal&#x02010;like breast cancer, the MAZ&#x02010;FOXF2 axis has a dual function of promoting proliferation and inhibiting migration [<xref rid="cam470977-bib-0037" ref-type="bibr">37</xref>], and MAZ did not significantly impact migration and invasion capabilities in papillary thyroid carcinoma [<xref rid="cam470977-bib-0038" ref-type="bibr">38</xref>]. Studies have shown that the knockdown of MAZ under acidic stimulation inhibits the EMT process in GC, thereby inhibiting GC cell migration [<xref rid="cam470977-bib-0037" ref-type="bibr">37</xref>]. On the contrary, our study shows that MAZ knockdown in GC cells significantly enhanced cell migration. Moreover, in our cohort of GC patients, we demonstrated that MAZ was highly expressed in GC tissues compared to adjacent normal tissues, but high expression of MAZ is associated with more prolonged overall survival of patients. All these contradictory findings suggest that the effect of MAZ on tumor metastasis is more complex than previously thought.</p><p>In this study, we demonstrated that MAZ splice isoforms exhibit distinct activities in GC migration; MAZ&#x02010;1 and MAZ&#x02010;3 inhibit GC cell migration, while MAZ&#x02010;2 exerts the opposite functions (Figure&#x000a0;<xref rid="cam470977-fig-0004" ref-type="fig">4C&#x02013;E</xref> and Figure&#x000a0;<xref rid="cam470977-supitem-0002" ref-type="supplementary-material">S1E</xref>). Until now, little is known about the function of MAZ&#x02010;2. Due to alternative splicing of the precursor mRNA, exon 6, which contains 225 nucleotides, is retained at the C&#x02010;terminus of MAZ&#x02010;2 mRNA. This splicing event causes the stop codon to appear prematurely, making the difference in the MAZ&#x02010;2 structure. Compared with MAZ&#x02010;1 and MAZ&#x02010;3, MAZ&#x02010;2 has two additional zinc finger structures at the C&#x02010;terminus, which makes MAZ&#x02010;2 have different transcriptional activities [<xref rid="cam470977-bib-0024" ref-type="bibr">24</xref>]. However, whether this is the reason why MAZ&#x02010;2 promotes GC cell migration needs to be further explored. We found that MAZ&#x02010;2 was highly expressed in GC tissues compared to adjacent normal tissues, but there was no significant difference between MAZ&#x02010;1 and MAZ&#x02010;3. Furthermore, the MAZ isoform ratio is associated with patient survival. Our results showed that the MAZ&#x02010;2 isoform ratio in STAD and ECSA (prognostic protective factors) was significantly lower than that in BLCA, KIRP, LIHC, and LUSC (prognostic risk factors) (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5I</xref>). Interestingly, we also found that the MAZ&#x02010;2 isoform ratios of the total in GC (pan&#x02010;MAZ inhibited cell migration), papillary thyroid carcinoma (pan&#x02010;MAZ did not affect cell migration), and hepatocellular carcinoma (pan&#x02010;MAZ promoted cell migration) were 53.27%, 60.76%, and 64.54%, respectively (Figure&#x000a0;<xref rid="cam470977-fig-0005" ref-type="fig">5I</xref>). These results indicate that the MAZ isoform ratio regulates cancer cell migration and is associated with patient prognosis.</p><p>To target MAZ alternative splicing, we screened PUF60, a splicing factor with significantly altered expression in GC. PUF60 is an RNA&#x02010;binding protein that has been identified as a component of the spliceosome and plays a key role in pre&#x02010;mRNA splicing [<xref rid="cam470977-bib-0039" ref-type="bibr">39</xref>]. Our RNA&#x02010;seq and RIP&#x02010;seq data revealed that PUF60 is a critical splicing regulator of MAZ; PUF60 could bind directly to MAZ transcripts. Recently, PUF60 has been reported to be involved in promoting cell cycle and lung cancer progression by regulating alternative splicing of CDC25C [<xref rid="cam470977-bib-0040" ref-type="bibr">40</xref>]. In addition, PUF60 is closely related to c&#x02010;myc transcription and tumor processing [<xref rid="cam470977-bib-0040" ref-type="bibr">40</xref>, <xref rid="cam470977-bib-0041" ref-type="bibr">41</xref>]. Interestingly, c&#x02010;myc was one of the first identified and most important target genes of MAZ [<xref rid="cam470977-bib-0004" ref-type="bibr">4</xref>]. We demonstrated that the mRNA abundance of MAZ&#x02010;2 was significantly upregulated under PUF60 knockdown conditions while promoting GC cell migration (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6F&#x02013;H</xref>). However, the reduced PUF60 level had no significant effect on migration when MAZ was knocked out (Figure&#x000a0;<xref rid="cam470977-fig-0006" ref-type="fig">6I</xref>). Therefore, these results suggest that PUF60 regulates GC cell migration by affecting MAZ alternative splicing. PUF60 and MAZ together play a critical role in the regulation of tumor progression.</p><p>In recent years, a variety of approaches targeting alternative splicing have been under clinical development, including inhibition of key splicing factors or modulation of specific AS events [<xref rid="cam470977-bib-0042" ref-type="bibr">42</xref>]. Our study demonstrated the opposing functions of MAZ isoforms in GC migration. MAZ&#x02010;2, which has the potential to increase migration, is highly expressed in tumors. We also provided evidence that the splicing factor PUF60 binds directly to MAZ transcripts. Notably, MAZ isoform ratios are altered during PUF60 knockdown. Using small molecules, antisense oligonucleotides, CRISPR&#x02010;based approaches or engineered small nuclear RNAs to target MAZ splice&#x02010;switching may be potential options for inhibiting metastasis in GC.</p></sec><sec id="cam470977-sec-0016"><title>Author Contributions</title><p>
<bold>Dong Xing:</bold> investigation (equal), validation (equal), writing &#x02013; original draft (equal). <bold>Ting Zhao:</bold> investigation (equal), validation (equal), writing &#x02013; original draft (equal), writing &#x02013; review and editing (equal). <bold>Chenchen Mao:</bold> data curation (equal), software (equal). <bold>Zheng Han:</bold> writing &#x02013; review and editing (equal). <bold>Teming Zhang:</bold> investigation (equal), methodology (equal). <bold>Dianfeng Mei:</bold> investigation (equal), validation (equal). <bold>Wangkai Xie:</bold> investigation (equal), methodology (equal). <bold>Jiaye Yu:</bold> resources (equal). <bold>Zhonghan Wu:</bold> resources (equal). <bold>Zhiyuan Chen:</bold> resources (equal). <bold>Shiyu Feng:</bold> resources (equal). <bold>Xian Shen:</bold> conceptualization (equal), funding acquisition (equal), resources (equal), supervision (equal). <bold>Xiangyang Xue:</bold> conceptualization (equal), funding acquisition (equal), project administration (equal), resources (equal), supervision (equal). <bold>Dan Xiang:</bold> data curation (equal), project administration (equal), software (equal), supervision (equal). <bold>Wanxia Cai:</bold> methodology (equal).</p></sec><sec id="cam470977-sec-0012"><title>Ethics Statement</title><p>All studies were approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (LCKY2020&#x02010;43). All patients provided written informed consent to participate in the study.</p></sec><sec sec-type="COI-statement" id="cam470977-sec-0013"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cam470977-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Data S1.</bold> Supporting Information.</p></caption><media xlink:href="CAM4-14-e70977-s004.docx"/></supplementary-material><supplementary-material id="cam470977-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Figure S1.</bold> (A) Genomic sequencing analysis of AGS partial knockout cells. (B) The proliferation of cells under MAZ knockout was determined via EdU assays. Scale bar, 100&#x02009;&#x003bc;m. (C, D) Western blot analysis and immunofluorescence to detect MAZ splice isoform localization in AGS cells expressing MAZ&#x02010;1&#x02010;HA, MAZ&#x02010;2&#x02010;HA, or MAZ&#x02010;3&#x02010;HA. Scale bar, 25&#x02009;&#x003bc;m. (E) Western blot analysis to the expression of EMT markers in AGS cells expressing MAZ&#x02010;1&#x02010;HA, and MAZ&#x02010;2&#x02010;HA.</p></caption><media xlink:href="CAM4-14-e70977-s003.jpg"/></supplementary-material><supplementary-material id="cam470977-supitem-0003" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> Sequences of gRNA and primers.</p></caption><media xlink:href="CAM4-14-e70977-s002.xlsx"/></supplementary-material><supplementary-material id="cam470977-supitem-0004" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S2.</bold> GO enrichment analysis of AGS MAZ KO cells.</p></caption><media xlink:href="CAM4-14-e70977-s001.xls"/></supplementary-material></sec></body><back><ack id="cam470977-sec-0011"><title>Acknowledgments</title><p>We are grateful for the funding support mentioned above.</p></ack><sec sec-type="data-availability" id="cam470977-sec-0015"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are included in this published article.</p></sec><ref-list content-type="cited-references" id="cam470977-bibl-0001"><title>References</title><ref id="cam470977-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam470977-cit-0001">
<string-name>
<given-names>H.</given-names>
<surname>Sung</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ferlay</surname>
</string-name>, <string-name>
<given-names>R. L.</given-names>
<surname>Siegel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>,&#x0201d; <source>CA: A Cancer Journal for Clinicians</source>
<volume>71</volume> (<year>2021</year>): <fpage>209</fpage>&#x02013;<lpage>249</lpage>, <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam470977-cit-0002">
<string-name>
<given-names>E. C.</given-names>
<surname>Smyth</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Nilsson</surname>
</string-name>, <string-name>
<given-names>H. I.</given-names>
<surname>Grabsch</surname>
</string-name>, <string-name>
<given-names>N. C. T.</given-names>
<surname>van Grieken</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Lordick</surname>
</string-name>, &#x0201c;<article-title>Gastric Cancer</article-title>,&#x0201d; <source>Lancet</source>
<volume>396</volume> (<year>2020</year>): <fpage>635</fpage>&#x02013;<lpage>648</lpage>.<pub-id pub-id-type="pmid">32861308</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam470977-cit-0003">
<string-name>
<given-names>Y. K.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Boku</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Satoh</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Nivolumab in Patients With Advanced Gastric or Gastro&#x02010;Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO&#x02010;4538&#x02010;12, ATTRACTION&#x02010;2): A Randomised, Double&#x02010;Blind, Placebo&#x02010;Controlled, Phase 3 Trial</article-title>,&#x0201d; <source>Lancet</source>
<volume>390</volume> (<year>2017</year>): <fpage>2461</fpage>&#x02013;<lpage>2471</lpage>, <pub-id pub-id-type="doi">10.1016/s0140-6736(17)31827-5</pub-id>.<pub-id pub-id-type="pmid">28993052</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam470977-cit-0004">
<string-name>
<given-names>S. A.</given-names>
<surname>Bossone</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Asselin</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Patel</surname>
</string-name>, and <string-name>
<given-names>K. B.</given-names>
<surname>Marcu</surname>
</string-name>, &#x0201c;<article-title>MAZ, a Zinc Finger Protein, Binds to c&#x02010;MYC and C2 Gene Sequences Regulating Transcriptional Initiation and Termination</article-title>,&#x0201d; <source>Proceedings of the National Academy of Sciences of the United States of America</source>
<volume>89</volume> (<year>1992</year>): <fpage>7452</fpage>&#x02013;<lpage>7456</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.89.16.7452</pub-id>.<pub-id pub-id-type="pmid">1502157</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam470977-cit-0005">
<string-name>
<given-names>M.</given-names>
<surname>Komatsu</surname>
</string-name>, <string-name>
<given-names>H. O.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Tsutsui</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Itakura</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Matsumura</surname>
</string-name>, and <string-name>
<given-names>K. K.</given-names>
<surname>Yokoyama</surname>
</string-name>, &#x0201c;<article-title>MAZ, a Myc&#x02010;Associated Zinc Finger Protein, Is Essential for the ME1a1&#x02010;Mediated Expression of the c&#x02010;Myc Gene During Neuroectodermal Differentiation of P19 Cells</article-title>,&#x0201d; <source>Oncogene</source>
<volume>15</volume> (<year>1997</year>): <fpage>1123</fpage>&#x02013;<lpage>1131</lpage>, <pub-id pub-id-type="doi">10.1038/sj.onc.1201283</pub-id>.<pub-id pub-id-type="pmid">9294605</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam470977-cit-0006">
<string-name>
<given-names>W. P.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>K. H.</given-names>
<surname>Lan</surname>
</string-name>, <string-name>
<given-names>C. P.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Chao</surname>
</string-name>, <string-name>
<given-names>H. C.</given-names>
<surname>Lin</surname>
</string-name>, and <string-name>
<given-names>S. D.</given-names>
<surname>Lee</surname>
</string-name>, &#x0201c;<article-title>Akt Phosphorylates Myc&#x02010;Associated Zinc Finger Protein (MAZ), Releases P&#x02010;MAZ From the p53 Promoter, and Activates p53 Transcription</article-title>,&#x0201d; <source>Cancer Letters</source>
<volume>375</volume> (<year>2016</year>): <fpage>9</fpage>&#x02013;<lpage>19</lpage>, <pub-id pub-id-type="doi">10.1016/j.canlet.2016.02.023</pub-id>.<pub-id pub-id-type="pmid">26902421</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam470977-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>Ray</surname>
</string-name> and <string-name>
<given-names>B. K.</given-names>
<surname>Ray</surname>
</string-name>, &#x0201c;<article-title>Induction of Ras by SAF&#x02010;1/MAZ Through a Feed&#x02010;Forward Loop Promotes Angiogenesis in Breast Cancer</article-title>,&#x0201d; <source>Cancer Medicine</source>
<volume>4</volume> (<year>2015</year>): <fpage>224</fpage>&#x02013;<lpage>234</lpage>, <pub-id pub-id-type="doi">10.1002/cam4.362</pub-id>.<pub-id pub-id-type="pmid">25449683</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam470977-cit-0008">
<string-name>
<given-names>M.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Katzenellenbogen</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Grandori</surname>
</string-name>, and <string-name>
<given-names>D. A.</given-names>
<surname>Galloway</surname>
</string-name>, &#x0201c;<article-title>An Unbiased In&#x000a0;Vivo Screen Reveals Multiple Transcription Factors That Control HPV E6&#x02010;Regulated hTERT in Keratinocytes</article-title>,&#x0201d; <source>Virology</source>
<volume>446</volume> (<year>2013</year>): <fpage>17</fpage>&#x02013;<lpage>24</lpage>, <pub-id pub-id-type="doi">10.1016/j.virol.2013.07.014</pub-id>.<pub-id pub-id-type="pmid">24074563</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam470977-cit-0009">
<string-name>
<given-names>M.</given-names>
<surname>Smits</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Wurdinger</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hof</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Myc&#x02010;Associated Zinc Finger Protein (MAZ) is Regulated by miR&#x02010;125b and Mediates VEGF&#x02010;Induced Angiogenesis in Glioblastoma</article-title>,&#x0201d; <source>FASEB Journal</source>
<volume>26</volume> (<year>2012</year>): <fpage>2639</fpage>&#x02013;<lpage>2647</lpage>, <pub-id pub-id-type="doi">10.1096/fj.11-202820</pub-id>.<pub-id pub-id-type="pmid">22415301</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam470977-cit-0010">
<string-name>
<given-names>D. D.</given-names>
<surname>Duncan</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Stupakoff</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Hedrick</surname>
</string-name>, <string-name>
<given-names>K. B.</given-names>
<surname>Marcu</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Siu</surname>
</string-name>, &#x0201c;<article-title>A Myc&#x02010;Associated Zinc Finger Protein Binding Site Is One of Four Important Functional Regions in the CD4 Promoter</article-title>,&#x0201d; <source>Molecular and Cellular Biology</source>
<volume>15</volume> (<year>1995</year>): <fpage>3179</fpage>&#x02013;<lpage>3186</lpage>.<pub-id pub-id-type="pmid">7760814</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam470977-cit-0011">
<string-name>
<given-names>M. M.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Comprehensive Analysis of the Tumor&#x02010;Promoting Effect and Immune Infiltration Correlation MAZ From Pan&#x02010;Cancer to Hepatocellular Carcinoma</article-title>,&#x0201d; <source>International Immunopharmacology</source>
<volume>115</volume> (<year>2023</year>): <fpage>13</fpage>, <pub-id pub-id-type="doi">10.1016/j.intimp.2022.109660</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam470977-cit-0012">
<string-name>
<given-names>Q.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Lang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MAZ Promotes Prostate Cancer Bone Metastasis Through Transcriptionally Activating the KRas&#x02010;Dependent RalGEFs Pathway</article-title>,&#x0201d; <source>Journal of Experimental &#x00026; Clinical Cancer Research</source>
<volume>38</volume>, no. <issue>1</issue> (<year>2019</year>): <elocation-id>1374</elocation-id>, <pub-id pub-id-type="doi">10.1186/s13046-019-1374-x</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam470977-cit-0013">
<string-name>
<given-names>L.</given-names>
<surname>Jiao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Shen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Prostate Cancer&#x02010;Up&#x02010;Regulated Myc&#x02010;Associated Zinc&#x02010;Finger Protein (MAZ) Modulates Proliferation and Metastasis Through Reciprocal Regulation of Androgen Receptor</article-title>,&#x0201d; <source>Medical Oncology</source>
<volume>30</volume>, no. <issue>2</issue> (<year>2013</year>): <elocation-id>570</elocation-id>, <pub-id pub-id-type="doi">10.1007/s12032-013-0570-3</pub-id>.<pub-id pub-id-type="pmid">23609189</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam470977-cit-0014">
<string-name>
<given-names>Y. L.</given-names>
<surname>Yao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Yao</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ma</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MiR&#x02010;449a Exerts Tumor&#x02010;Suppressive Functions in Human Glioblastoma by Targeting Myc&#x02010;Associated Zinc&#x02010;Finger Protein</article-title>,&#x0201d; <source>Molecular Oncology</source>
<volume>9</volume> (<year>2015</year>): <fpage>640</fpage>&#x02013;<lpage>656</lpage>, <pub-id pub-id-type="doi">10.1016/j.molonc.2014.11.003</pub-id>.<pub-id pub-id-type="pmid">25487955</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam470977-cit-0015">
<string-name>
<given-names>C. J.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Roles of Myc&#x02010;Associated Zinc Finger Protein in Malignant Tumors</article-title>,&#x0201d; <source>Asia&#x02010;Pacific Journal of Clinical Oncology</source>
<volume>18</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>506</fpage>&#x02013;<lpage>514</lpage>, <pub-id pub-id-type="doi">10.1111/ajco.13748</pub-id>.<pub-id pub-id-type="pmid">35098656</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam470977-cit-0016">
<string-name>
<given-names>H.</given-names>
<surname>Ortabozkoyun</surname>
</string-name>, <string-name>
<given-names>P. Y.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Cho</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CRISPR and Biochemical Screens Identify MAZ as a Cofactor in CTCF&#x02010;Mediated Insulation at <italic toggle="yes">Hox</italic> Clusters</article-title>,&#x0201d; <source>Nature Genetics</source>
<volume>54</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>202</fpage>, <pub-id pub-id-type="doi">10.1038/s41588-021-01008-5</pub-id>.<pub-id pub-id-type="pmid">35145304</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam470977-cit-0017">
<string-name>
<given-names>L. M.</given-names>
<surname>Gallego&#x02010;Paez</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Bordone</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Leote</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Saraiva&#x02010;Agostinho</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ascens&#x000e3;o&#x02010;Ferreira</surname>
</string-name>, and <string-name>
<given-names>N. L.</given-names>
<surname>Barbosa&#x02010;Morais</surname>
</string-name>, &#x0201c;<article-title>Alternative Splicing: The Pledge, the Turn, and the Prestige. The Key Role of Alternative Splicing in Human Biological Systems</article-title>,&#x0201d; <source>Human Genetics</source>
<volume>136</volume> (<year>2017</year>): <fpage>1015</fpage>&#x02013;<lpage>1042</lpage>, <pub-id pub-id-type="doi">10.1007/s00439-017-1790-y</pub-id>.<pub-id pub-id-type="pmid">28374191</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam470977-cit-0018">
<string-name>
<given-names>S. C.</given-names>
<surname>Bonnal</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Lopez&#x02010;Oreja</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Valcarcel</surname>
</string-name>, &#x0201c;<article-title>Roles and Mechanisms of Alternative Splicing in Cancer&#x02014;Implications for Care</article-title>,&#x0201d; <source>Nature Reviews Clinical Oncology</source>
<volume>17</volume> (<year>2020</year>): <fpage>457</fpage>&#x02013;<lpage>474</lpage>, <pub-id pub-id-type="doi">10.1038/s41571-020-0350-x</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam470977-cit-0019">
<string-name>
<given-names>L. H.</given-names>
<surname>Boise</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gonz&#x000e1;lez&#x02010;Garc&#x000ed;a</surname>
</string-name>, <string-name>
<given-names>C. E.</given-names>
<surname>Postema</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Bcl&#x02010;x, a Bcl&#x02010;2&#x02010;Related Gene That Functions as a Dominant Regulator of Apoptotic Cell Death</article-title>,&#x0201d; <source>Cell</source>
<volume>74</volume> (<year>1993</year>): <fpage>597</fpage>&#x02013;<lpage>608</lpage>.<pub-id pub-id-type="pmid">8358789</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam470977-cit-0020">
<string-name>
<given-names>H. K.</given-names>
<surname>Gan</surname>
</string-name>, <string-name>
<given-names>A. N.</given-names>
<surname>Cvrljevic</surname>
</string-name>, and <string-name>
<given-names>T. G.</given-names>
<surname>Johns</surname>
</string-name>, &#x0201c;<article-title>The Epidermal Growth Factor Receptor Variant III (EGFRvIII): Where Wild Things Are Altered</article-title>,&#x0201d; <source>FEBS Journal</source>
<volume>280</volume> (<year>2013</year>): <fpage>5350</fpage>&#x02013;<lpage>5370</lpage>, <pub-id pub-id-type="doi">10.1111/febs.12393</pub-id>.<pub-id pub-id-type="pmid">23777544</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam470977-cit-0021">
<string-name>
<given-names>E. C.</given-names>
<surname>Piccione</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Lieu</surname>
</string-name>, <string-name>
<given-names>C. F.</given-names>
<surname>Gentile</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Novel Epidermal Growth Factor Receptor Variant Lacking Multiple Domains Directly Activates Transcription and Is Overexpressed in Tumors</article-title>,&#x0201d; <source>Oncogene</source>
<volume>31</volume> (<year>2012</year>): <fpage>2953</fpage>&#x02013;<lpage>2967</lpage>, <pub-id pub-id-type="doi">10.1038/onc.2011.465</pub-id>.<pub-id pub-id-type="pmid">21986942</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam470977-cit-0022">
<string-name>
<given-names>J. B.</given-names>
<surname>Cohen</surname>
</string-name>, <string-name>
<given-names>S. D.</given-names>
<surname>Broz</surname>
</string-name>, and <string-name>
<given-names>A. D.</given-names>
<surname>Levinson</surname>
</string-name>, &#x0201c;<article-title>Expression of the H&#x02010;Ras Proto&#x02010;Oncogene Is Controlled by Alternative Splicing</article-title>,&#x0201d; <source>Cell</source>
<volume>58</volume> (<year>1989</year>): <fpage>461</fpage>&#x02013;<lpage>472</lpage>, <pub-id pub-id-type="doi">10.1016/0092-8674(89)90427-3</pub-id>.<pub-id pub-id-type="pmid">2667764</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam470977-cit-0023">
<string-name>
<given-names>J. K.</given-names>
<surname>Voice</surname>
</string-name>, <string-name>
<given-names>R. L.</given-names>
<surname>Klemke</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Le</surname>
</string-name>, and <string-name>
<given-names>J. H.</given-names>
<surname>Jackson</surname>
</string-name>, &#x0201c;<article-title>Four Human Ras Homologs Differ in Their Abilities to Activate Raf&#x02010;1, Induce Transformation, and Stimulate Cell Motility</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>274</volume> (<year>1999</year>): <fpage>17164</fpage>&#x02013;<lpage>17170</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.274.24.17164</pub-id>.<pub-id pub-id-type="pmid">10358073</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam470977-cit-0024">
<string-name>
<given-names>B. K.</given-names>
<surname>Ray</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Murphy</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Ray</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Ray</surname>
</string-name>, &#x0201c;<article-title>SAF&#x02010;2, a Splice Variant of SAF&#x02010;1, Acts as a Negative Regulator of Transcription</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>277</volume> (<year>2002</year>): <fpage>46822</fpage>&#x02013;<lpage>46830</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M206299200</pub-id>.<pub-id pub-id-type="pmid">12270922</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam470977-cit-0025">
<string-name>
<given-names>A.</given-names>
<surname>Ray</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dhar</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Shakya</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Ray</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Okada</surname>
</string-name>, and <string-name>
<given-names>B. K.</given-names>
<surname>Ray</surname>
</string-name>, &#x0201c;<article-title>SAF&#x02010;3, a Novel Splice Variant of the SAF&#x02010;1/MAZ/Pur&#x02010;1 Family, Is Expressed During Inflammation</article-title>,&#x0201d; <source>FEBS Journal</source>
<volume>276</volume> (<year>2009</year>): <fpage>4276</fpage>&#x02013;<lpage>4286</lpage>, <pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07136.x</pub-id>.<pub-id pub-id-type="pmid">19583771</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam470977-cit-0026">
<string-name>
<given-names>T. W.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Fu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>TIMER2.0 for Analysis of Tumor&#x02010;Infiltrating Immune Cells</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>48</volume> (<year>2020</year>): <fpage>W509</fpage>&#x02013;<lpage>W514</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkaa407</pub-id>.<pub-id pub-id-type="pmid">32442275</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam470977-cit-0027">
<string-name>
<given-names>Z. F.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>B. X.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>C. W.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>T. X.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>Z. M.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>GEPIA2: An Enhanced Web Server for Large&#x02010;Scale Expression Profiling and Interactive Analysis</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>47</volume> (<year>2019</year>): <fpage>W556</fpage>&#x02013;<lpage>W560</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkz430</pub-id>.<pub-id pub-id-type="pmid">31114875</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam470977-cit-0028">
<string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MAZ Promotes Tumor Proliferation and Immune Evasion in Lung Adenocarcinoma</article-title>,&#x0201d; <source>Oncogene</source>
<volume>14</volume> (<year>2024</year>): <fpage>1</fpage>&#x02013;<lpage>14</lpage>, <pub-id pub-id-type="doi">10.1038/s41388-024-03194-y</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam470977-cit-0029">
<string-name>
<given-names>W. J.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Duan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>TSVdb: A Web&#x02010;Tool for TCGA Splicing Variants Analysis</article-title>,&#x0201d; <source>BMC Genomics</source>
<volume>19</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>1</fpage>&#x02013;<lpage>7</lpage>, <pub-id pub-id-type="doi">10.1186/s12864-018-4775-x</pub-id>.<pub-id pub-id-type="pmid">29291715</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam470977-cit-0030">
<string-name>
<given-names>D. X.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Hu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Intron Retention Is a Hallmark and Spliceosome Represents a Therapeutic Vulnerability in Aggressive Prostate Cancer</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>19</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-020-15815-7</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam470977-cit-0031">
<string-name>
<given-names>J.</given-names>
<surname>Chen</surname>
</string-name> and <string-name>
<given-names>W. A.</given-names>
<surname>Weiss</surname>
</string-name>, &#x0201c;<article-title>Alternative Splicing in Cancer: Implications for Biology and Therapy</article-title>,&#x0201d; <source>Oncogene</source>
<volume>34</volume> (<year>2015</year>): <fpage>1</fpage>&#x02013;<lpage>14</lpage>, <pub-id pub-id-type="doi">10.1038/onc.2013.570</pub-id>.<pub-id pub-id-type="pmid">24441040</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam470977-cit-0032">
<string-name>
<given-names>S. G.</given-names>
<surname>Thrumurthy</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Chaudry</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Chau</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Allum</surname>
</string-name>, &#x0201c;<article-title>Does Surgery Have a Role in Managing Incurable Gastric Cancer?</article-title>,&#x0201d; <source>Nature Reviews. Clinical Oncology</source>
<volume>12</volume> (<year>2015</year>): <fpage>676</fpage>&#x02013;<lpage>682</lpage>, <pub-id pub-id-type="doi">10.1038/nrclinonc.2015.132</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam470977-cit-0033">
<string-name>
<given-names>N. Y.</given-names>
<surname>Chia</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Deng</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>das</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Regulatory Crosstalk Between Lineage&#x02010;Survival Oncogenes KLF5, GATA4 and GATA6 Cooperatively Promotes Gastric Cancer Development</article-title>,&#x0201d; <source>Gut</source>
<volume>64</volume> (<year>2015</year>): <fpage>707</fpage>&#x02013;<lpage>719</lpage>, <pub-id pub-id-type="doi">10.1136/gutjnl-2013-306596</pub-id>.<pub-id pub-id-type="pmid">25053715</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam470977-cit-0034">
<string-name>
<given-names>M.</given-names>
<surname>Razavi&#x02010;Mohseni</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>Y. A.</given-names>
<surname>Guo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Machine Learning Identifies Activation of RUNX/AP&#x02010;1 as Drivers of Mesenchymal and Fibrotic Regulatory Programs in Gastric Cancer</article-title>,&#x0201d; <source>Genome Research</source>
<volume>34</volume> (<year>2024</year>): <fpage>680</fpage>&#x02013;<lpage>695</lpage>, <pub-id pub-id-type="doi">10.1101/gr.278565.123</pub-id>.<pub-id pub-id-type="pmid">38777607</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam470977-cit-0035">
<string-name>
<given-names>S. W. T.</given-names>
<surname>Ho</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Sheng</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Xing</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Regulatory Enhancer Profiling of Mesenchymal&#x02010;Type Gastric Cancer Reveals Subtype&#x02010;Specific Epigenomic Landscapes and Targetable Vulnerabilities</article-title>,&#x0201d; <source>Gut</source>
<volume>72</volume> (<year>2023</year>): <fpage>226</fpage>&#x02013;<lpage>241</lpage>, <pub-id pub-id-type="doi">10.1136/gutjnl-2021-326483</pub-id>.<pub-id pub-id-type="pmid">35817555</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam470977-cit-0036">
<string-name>
<given-names>R. H.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zuo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Downregulation of <italic toggle="yes">nc886</italic> Contributes to Prostate Cancer Cell Invasion and TGF&#x003b2;1&#x02010;Induced EMT</article-title>,&#x0201d; <source>Genes &#x00026; Diseases</source>
<volume>9</volume> (<year>2022</year>): <fpage>1086</fpage>&#x02013;<lpage>1098</lpage>, <pub-id pub-id-type="doi">10.1016/j.gendis.2020.12.010</pub-id>.<pub-id pub-id-type="pmid">35685460</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam470977-cit-0037">
<string-name>
<given-names>Z. H.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Lun</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>He</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Dual Function of MAZ Mediated by FOXF2 in Basal&#x02010;Like Breast Cancer: Promotion of Proliferation and Suppression of Progression</article-title>,&#x0201d; <source>Cancer Letters</source>
<volume>402</volume> (<year>2017</year>): <fpage>142</fpage>&#x02013;<lpage>152</lpage>, <pub-id pub-id-type="doi">10.1016/j.canlet.2017.05.020</pub-id>.<pub-id pub-id-type="pmid">28577976</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cam470977-cit-0038">
<string-name>
<given-names>J. J.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MAZ Promotes Thyroid Cancer Progression by Driving Transcriptional Reprogram and Enhancing ERK1/2 Activation</article-title>,&#x0201d; <source>Cancer Letters</source>
<volume>602</volume> (<year>2024</year>): <fpage>11</fpage>, <pub-id pub-id-type="doi">10.1016/j.canlet.2024.217201</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cam470977-cit-0039">
<string-name>
<given-names>N.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ren</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Bao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>PUF60 Promotes Cell Cycle and Lung Cancer Progression by Regulating Alternative Splicing of <italic toggle="yes">CDC25C</italic>
</article-title>,&#x0201d; <source>Cell Reports</source>
<volume>42</volume> (<year>2023</year>): <fpage>20</fpage>, <pub-id pub-id-type="doi">10.1016/j.celrep.2023.113041</pub-id>.</mixed-citation></ref><ref id="cam470977-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cam470977-cit-0040">
<string-name>
<given-names>D. Y.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Lei</surname>
</string-name>, <string-name>
<given-names>X. D.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>W. L.</given-names>
<surname>Ni</surname>
</string-name>, &#x0201c;<article-title>PUF60 Accelerates the Progression of Breast Cancer Through Downregulation of PTEN Expression</article-title>,&#x0201d; <source>Cancer Management and Research</source>
<volume>11</volume> (<year>2019</year>): <fpage>821</fpage>&#x02013;<lpage>830</lpage>, <pub-id pub-id-type="doi">10.2147/cmar.S180242</pub-id>.<pub-id pub-id-type="pmid">30697074</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cam470977-cit-0041">
<string-name>
<given-names>K.</given-names>
<surname>Matsushita</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tamura</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Tanaka</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interactions Between SAP155 and FUSE&#x02010;Binding Protein&#x02010;Interacting Repressor Bridges c&#x02010;Myc and P27Kip1 Expression</article-title>,&#x0201d; <source>Molecular Cancer Research</source>
<volume>11</volume> (<year>2013</year>): <fpage>689</fpage>&#x02013;<lpage>698</lpage>, <pub-id pub-id-type="doi">10.1158/1541-7786.Mcr-12-0673</pub-id>.<pub-id pub-id-type="pmid">23594796</pub-id>
</mixed-citation></ref><ref id="cam470977-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cam470977-cit-0042">
<string-name>
<given-names>R. K.</given-names>
<surname>Bradley</surname>
</string-name> and <string-name>
<given-names>O.</given-names>
<surname>Anczuk&#x000f3;w</surname>
</string-name>, &#x0201c;<article-title>RNA Splicing Dysregulation and the Hallmarks of Cancer</article-title>,&#x0201d; <source>Nature Reviews Cancer</source>
<volume>23</volume> (<year>2023</year>): <fpage>135</fpage>&#x02013;<lpage>155</lpage>, <pub-id pub-id-type="doi">10.1038/s41568-022-00541-7</pub-id>.<pub-id pub-id-type="pmid">36627445</pub-id>
</mixed-citation></ref></ref-list></back></article>